DXCM vs MXCT · P/E 63, rev $2.50B vs rev $16.9M
DexCom Inc (DXCM) versus MaxCyte Inc (MXCT) — a side-by-side from cached financials, not a winner call.
DexCom Inc (DXCM) is a medical devices company listed on US.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Latest reported DXCM revenue for 2026-06-30 was $2.50B. Net income was $448.6M. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
Latest reported MXCT revenue for 2026-06-30 was $16.9M. Net income was -$13.6M. Revenue was up 75.3% from 2026-03-31 to 2026-06-30. MXCT currently screens at market cap $124.3M.
DXCM currently screens at market cap $32.84B and trailing P/E 62.5. MXCT currently screens at market cap $124.3M.
Not investment advice. Open the DXCM and MXCT stock pages for the full models.
Not investment advice.